MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

130.90
-2.22
-1.67%
After Hours: 130.90 0 0.00% 16:30 09/18 EDT
OPEN
131.77
PREV CLOSE
133.12
HIGH
131.78
LOW
128.35
VOLUME
342.16K
TURNOVER
--
52 WEEK HIGH
179.57
52 WEEK LOW
105.19
MARKET CAP
7.90B
P/E (TTM)
-11.6219
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BGNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BGNE News

  • ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  • GlobeNewswire.10h ago
  • BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud
  • GlobeNewswire.1d ago
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE
  • ACCESSWIRE.2d ago
  • Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors
  • Business Wire.2d ago

More

Industry

Biotechnology & Medical Research
-0.65%
Pharmaceuticals & Medical Research
-0.05%

Hot Stocks

Name
Price
%Change

About BGNE

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More

Webull offers Beigene Ltd (ADR) (BGNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.